Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Biometrics|July 26, 2017
Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment RulesEmily L Butler, Eric B Laber, Sonia M Davis, et al.
Schizophrenia Bulletin|August 12, 2003
Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studiesSonia M Davis, Gary G Koch, C E Davis, et al.
Schizophrenia Research|June 24, 2009
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trialRobert A Rosenheck, Vicki G Davis, Sonia M Davis, et al.
The American Journal of Psychiatry|December 8, 2006
Effectiveness of switching antipsychotic medicationsSusan M Essock, Nancy H Covell, Sonia M Davis, et al.
Statistics in Biopharmaceutical Research|April 30, 2019
Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia StudySonia M Davis, T Scott Stroup, Gary G Koch, et al.
Archives of General Psychiatry|August 2, 2002
Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placeboJames H Kocsis, Alan Schatzberg, A John Rush, et al.
Schizophrenia Research|August 4, 2006
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baselineHenry A Nasrallah, Jonathan M Meyer, Donald C Goff, et al.
General Hospital Psychiatry|January 13, 2009
The impact of obesity on health care costs among persons with schizophreniaLydia A Chwastiak, Robert A Rosenheck, Joseph P McEvoy, et al.
Schizophrenia Research|September 22, 2009
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trialDavid L Penn, Richard S E Keefe, Sonia M Davis, et al.
The Journal of Clinical Psychiatry|September 28, 2010
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophreniaDonald E Addington, Somaia Mohamed, Robert A Rosenheck, et al.
Pageof 5